SCHEMBL5487845

SCHEMBL5487845

COC(=O)c1ccccc1OCC(=O)NO

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.63
TSHR P16473 3/20 0.63
SLC6A3 Q01959 1/20 0.51
HSD17B10 Q99714 3/20 0.51
MAPK10 P53779 1/20 0.51
MAPT P10636 3/20 0.50
HTT P42858 3/20 0.50
GAA P10253 1/20 0.50
HSP90AA1 P07900 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
KMT2A Q03164 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8399356 0.85 ALDH1A1 (0.59) ALDH1A1TSHRSLC6A3HSD17B10MAPT
SCHEMBL5481768 0.83 KDM4E (0.65) ALDH1A1TSHRHSD17B10MAPTHTT
SCHEMBL1280991 0.83 POLB (0.64) ALDH1A1TSHRSLC6A3MAPTHTT
SCHEMBL3783343 0.83 ALDH1A1 (0.58) ALDH1A1TSHRSLC6A3HSD17B10MAPT
SCHEMBL20235217 0.83 NPC1 (0.63) ALDH1A1TSHRSLC6A3HSD17B10MAPK10
SCHEMBL27524567 0.82 ALDH1A1 (0.57) ALDH1A1TSHRSLC6A3HSD17B10MAPT
SCHEMBL15285430 0.82 NPC1 (0.71) ALDH1A1TSHRMAPTHTTCYP2C9
SCHEMBL6538497 0.81 ALDH1A1 (0.56) ALDH1A1TSHRSLC6A3HSD17B10MAPK10
SCHEMBL8379922 0.81 ALDH1A1 (0.56) ALDH1A1TSHRSLC6A3MAPTHTT
SCHEMBL1989129 0.80 HCRTR1 (0.65) ALDH1A1TSHRSLC6A3MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040186081-A1 Naaladase inhibitors for treating opioid tolerance GUILFORD PHARMACEUTICALS INC. 2004-09-23 US claimed
WO-2004078180-A2 NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE GUILFORD PHARMACEUTICALS INC. (US) 2004-09-16 WO claimed
EP-1292601-A2 NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA GUILFORD PHARMACEUTICALS INC. (US) 2003-03-19 EP claimed
US-20030036534-A1 Naaladase inhibitors for treating retinal disorders and glaucoma EISAI INC. 2003-02-20 US claimed
WO-2001092274-A2 NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA GUILFORD PHARMACEUTICALS INC. (US) 2001-12-06 WO claimed
US-7220780-B2 Naaladase inhibitors for treating retinal disorders and glaucoma GUILFORD PHARMACEUTICALS INC. (US) 2007-05-22 US disclosed
US-7220780-B2 Naaladase inhibitors for treating retinal disorders and glaucoma GUILFORD PHARMACEUTICALS INC. (US) 2007-05-22 US disclosed
US-7220780-B2 Naaladase inhibitors for treating retinal disorders and glaucoma GUILFORD PHARMACEUTICALS INC. (US) 2007-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186081-A1 Naaladase inhibitors for treating opioid tolerance OPRD1, OPRK1, OPRM1 ALDH1A1 105/4885TSHR 4169/4885SLC6A3 47/4885
US-20030036534-A1 Naaladase inhibitors for treating retinal disorders and glaucoma ALDH1A2, GAA, PDE6A ALDH1A1 198/4885TSHR 3404/4885SLC6A3 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.